Cargando…
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
Immunostimulatory gene therapy has been developed during the past twenty years. The aim of immunostimulatory gene therapy is to tilt the suppressive tumor microenvironment to promote anti-tumor immunity. Hence, like a Trojan horse, the gene vehicle can carry warriors and weapons into enemy territory...
Autor principal: | Loskog, Angelica |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664972/ https://www.ncbi.nlm.nih.gov/pubmed/26561829 http://dx.doi.org/10.3390/v7112899 |
Ejemplares similares
-
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
por: Labani-Motlagh, Alireza, et al.
Publicado: (2021) -
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
por: Wenthe, Jessica, et al.
Publicado: (2020) -
Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts
por: Huang, Jing Li, et al.
Publicado: (2016) -
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
por: Loskog, Angelica, et al.
Publicado: (2016) -
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
por: Irenaeus, Sandra, et al.
Publicado: (2017)